Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
198 (255 working days)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
KEYTRUDA (powder for concentrated injection) in combination with LENVIMA (lenvatinib) is now also indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).